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Objective: This study compared the ability of generic and disease-specific questionnaires to assess quality of life (QOL) at
baseline and to detect change in QOL after treatment in patients with peripheral arterial disease (PAD).
Methods: This prospective multicenter trial recruited 514 patients with PAD who needed an imaging workup and had an
ankle brachial pressure index of less than 0.90. Patients with severe comorbidity were excluded, leaving a study
population of 450 patients. Patients completed two generic questionnaires, the Short Form 36 (SF-36) and the European
Quality of Life 5D (EuroQol-5D), and one disease-specific questionnaire, the Vascular Quality of Life (VascuQol) at
baseline and after 6 months of follow-up. Rutherford classification and treadmill walking distance were determined at
baseline and after 6 months of follow-up and were considered indicators of disease severity. Receiver operating
characteristic (ROC) curves and areas under the curves (AUCs) were used to evaluate each of the three questionnaires for
its ability to discriminate between severe andmild disease at baseline and to discriminate between a large and small change
in disease severity after follow-up. The underlying assumption was that disease severity is a major determinant of QOL.
This implies that the validity of a QOL questionnaire is reflected by its ability to discriminate between mildly and severely
diseased patients.
Results: At baseline, 443 patients and after follow-up, 386 patients completed questionnaires. At baseline, no significant
(P>.05) differences were observed among AUCs for the total scores of the three questionnaires, indicating that all three
questionnaires assessed the disease severity equally well. After follow-up, the AUCs for the VascuQol were significantly
higher than the AUCs for the SF-36 and EuroQol-5D with respect to detection of improvement in Rutherford
classification (P < .05), indicating that change in disease severity after follow-up was best detected by the VascuQol.
Conclusion: The VascuQol is the preferred questionnaire as outcome measure for QOL in future trials and clinical
follow-up of patients with PAD. (J Vasc Surg 2005;41:261-8.)Peripheral arterial disease (PAD) is a chronic condition
with a highmorbidity that is reflected in an impaired quality
of life (QOL).1-3 The major treatment goal for PAD is to
improve functional status of the patient and to relieve
disability. Treatment of PAD is usually evaluated in terms
of clinical parameters such as Rutherford classification,
ankle brachial pressure index (ABPI), and walking distance.
A major drawback of these clinical parameters is that they
poorly reflect the perspective of the patient after treat-
ment.4-6 As a result, several studies propose the measure-
ment ofQOL as a primary endpoint in evaluating treatment
effects.7-11 These studies have, however, used a wide variety
From the Departments of Radiology,a Cardiovascular Research Institute
Maastricht (CARIM),b Clinical Epidemiology and Medical Technology
Assessment,c Epidemiology,d and Care and Public Health Research Insti-
tute (CAPHRI),e Maastricht University Hospital, Maastricht; and De-
partment of Radiologyf and Epidemiology and Biostatistics,g Erasmus
MC Rotterdam, Rotterdam, Netherlands.
Competition of interest: none.
Reprint requests: Patricia J. Nelemans, MD, PhD, Department of Epidemi-
ology, Maastricht University Hospital, P. Debyeplein 1, 6229 HA Maas-
tricht, Netherlands (e-mail: Patty.Nelemans@epid.unimaas.nl).
0741-5214/$30.00
Copyright © 2005 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2004.11.022of different questionnaires to evaluate QOL because it is
still unclear which questionnaire best serves this purpose.
One approach to measure QOL is the use of generic
health questionnaires such as the Short Form 36 (SF-36) or
the European Quality of Life 5D (EuroQol-5D), which
measure physical, social, and emotional dimensions of
health. The advantage of generic questionnaires is that they
can be used for evaluating QOL for many types of diseases
and for calculating utility values in cost-effectiveness anal-
ysis. However, these generic questionnaires are considered
to be less sensitive to detect small but clinically important
differences in treatment effects because they do not focus
on specific effects of disease.12
Another approach for assessing QOL is the use of
disease-specific questionnaires in patients with PAD, such
as the Vascular Quality of Life (VascuQol).9 The VascuQol
measures more specific elements of PAD and thus, theoret-
ically, is more responsive to measure more subtle effects
after treatment.13
To date, little is known about the comparative validity
between generic and disease-specific questionnaires in pa-
tients with PAD. Comparative studies are needed to deter-
mine which questionnaire has the best ability to assess QOL
at baseline and to capture change in QOL after treatment.
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mainly for validation of the VascuQol instead of determin-
ing which questionnaire should be preferred in the assess-
ment of QOL in patients with PAD. The present study
compared the ability of generic versus disease-specific ques-
tionnaires to assess QOL at baseline and to detect change in
QOL after treatment in patients with PAD.
MATERIAL AND METHODS
Patients and questionnaires. The present study was
part of a large prospective Dutch multicenter study in
which patients with PAD were randomized between mag-
netic resonance (MR) angiography and the locally em-
ployed imaging protocol, either duplex scan or computed
tomography (CT) angiography, to compare imaging
work-up strategies. Four centers in the Netherlands partic-
ipated in the study.
Between December 2001 and September 2003, all
patients with PAD who needed an imaging workup to
evaluate the feasibility and choice of revascularization pro-
cedure were included. The study population consisted of
514 patients with intermittent claudication or critical isch-
emia and an ankle brachial pressure index (ABPI) of less
than 0.90. Clinical utility, patient outcome, and costs be-
tween the different imaging work-up strategies were com-
pared. For this purpose, clinical parameters and QOL were
collected at baseline and 6 months after the imaging
work-up (Fig 1).
Excluded because they could not participate in the
randomized trial were patients who needed an imaging
workup within 3 days, patients with contraindications for
MR angiography and CT angiography, and patients who
had already had an imaging workup indicating that revas-
cularization was needed. The present study also excluded
patients with severe comorbidity in order to avoid the
influence of comorbidities affecting QOL on the compari-
son of disease-specific and generic questionnaires. Of the
514 patients who were included in the study, 64 patients
with severe comorbid diseases were excluded, leaving a
study population of 450 patients without severe comorbid-
ity.
All patients signed written informed consent prior to
the randomization. All patients completed two generic
questionnaires (SF-36 and EuroQol-5D) and a disease-
specific questionnaire (VascuQol). Patients returned their
questionnaires by mail at baseline and 6 months after their
imaging work-up.
Short Form 36. The SF-36, a well-established generic
questionnaire, has often been used for patients with various
diseases.14 The SF-36 comprises eight different health di-
mensions; in the present study, we used four: physical
functioning (10 items), role physical functioning (4 items),
bodily pain (2 items), and general health (5 items). We
selected these four dimensions because these have been
shown to be the most responsive for measuring changes in
QOL after treatment of patients with PAD.8,13,15 Patients’
responses were converted to a scale ranging from 0 (worst
possible score) to 100 (best possible score).EuroQol-5D. The other generic questionnaire used
was the EuroQol-5D. It contains five questions regarding
mobility, self-care, usual activities, pain, and anxiety/de-
pression, with each having three levels of severity corre-
sponding to “no problems” (level 1) to “some problems”
(level 2), and “extreme problems” (level 3). The responses
of the patients were converted to a scale ranging from1 to
1.16
VascuQol. The VascuQol was developed as a disease-
specific questionnaire for patients with PAD. It contains 25
items (questions) subdivided into 5 dimensions: pain,
symptoms, activities, social, and emotional. Each question
has a 7-point response option. Patients’ responses were
converted to a scale ranging from 1 (worst possible score)
to 7 (best possible score).13
Data analysis. Data were analyzed at the level of the
symptomatic leg, defined as the leg in which treatment was
performed. If both legs were treated, or if the patient was
treated conservatively, the symptomatic leg was defined as
the leg with the most severe symptoms according to the
patient at baseline. In patients where symptoms at baseline
were comparable in both legs, we selected a leg with the
lowest ABPI. When patients with critical ischemia could
not complete a walking treadmill test because of severe pain
complaints in their legs, the missing value for walking
distance was imputed by the worst possible score. Missing
items on returned questionnaires were imputed using the
mean value of that variable. Patients who did not return
questionnaires were excluded from the respective analysis.
Because there is no gold standard for QOL, an impor-
tant assumption underlying the analysis was that disease
severity is a major determinant of QOL. This implies that
the construct validity of aQOL questionnaire is reflected by
its ability to discriminate between severely and less severely
diseased patients. To make this assumption more plausible,
patients with severe comorbidity (which is another impor-
tant determinant of QOL) were excluded from analysis.17
Comorbidity was defined as a myocardial infarction within
the previous 6 months, a cerebrovascular accident, or se-
vere renal failure needing dialysis.
Moreover, the natural course of patients with critical
ischemia is malignant owing to highmortality in contrast to
the often-benign natural course for patients with claudica-
tion. As a result, the relevance of QOL measurements in
patients with claudication and critical ischemia has different
aspects; therefore, the comparative validity of the question-
naires was assessed separately for patients with claudication
and those with critical ischemia.
The cross-sectional construct validity was assessed for all
three questionnaires. It was assumed that the cross-
sectional construct validity of a questionnaire is reflected by
its ability to discriminate at baseline between patients with
mild and severe disease by showing lower QOL scores in
more severely diseased patients. The Rutherford classifica-
tion and treadmill walking distance were the indicators
used for disease severity. The median values of these indi-
cators were used as cut-off points to classify patients into
two groups of equal size with severe versus less severe
e 386
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efficient.
Likewise, the longitudinal construct validity was as-
sessed for all three questionnaires. It was assumed that the
longitudinal construct validity of a questionnaire is re-
flected by its ability to capture change in QOL after treat-
ment by showing larger changes in QOL scores in patients
with larger changes in disease severity. Changes in indica-
tors for disease severity (Rutherford classification and tread-
mill walking distance) were calculated by subtracting the
baseline score from the score measured 6 months after the
date of the diagnostic exam. Again, the median values of
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Fig 1. Flow diagram of the study and data collection.
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mild disease at baseline and to detect change during follow-
up. The method of Hanley et al18 was used to test statistical
differences between the AUCs ( P  .05).
The primary analysis consisted of comparing AUCs
based on total scores on each questionnaire. For calculating
the total score on the SF-36, we used the algorithm of
Brazier et al.19,20 This algorithm uses 6 out of 8 dimensions
and requires information on 11 of the original 36 items. In
our study, only three dimensions and six items were avail-
able. We selected four dimensions because these have
shown to be the most responsive for measuring changes in
QOL after treatment of patients with PAD.8,13,15 Missing
items in our study were set to zero in the Brazier et al
algorithm.
In additional analyses, we compared AUCs based on
Table I. Baseline characteristics of patients who returned
questionnaires after follow-up
Characteristics of 386
patients
Claudication
(%)
Critical
ischemia
No. of patients 348 38
Male/female 230 (66)/
118 (34)
24 (63)/
14 (37)
Age (mean  SD) 64  11 65  12
Medical history
Tobacco use (ever/
never)
325 (93)/23 (7) 35 (92)/3 (8)
Diabetes mellitus 62 (18) 20 (53)
Hypertension 162 (47) 21 (55)
Hyperlipidemia 174* (50) 16* (42)
Renal disease 13* (4) 3* (8)
Mild renal insufficiency 3 (1) 4 (11)
Renal transplant 10 (3) 3 (8)
Cardiac disease 61 (18) 6 (16)
Congestive heart
failure
36 (10) 2 (5)
Myocardial infarction
 6 months ago
20 (6) 3 (8)
Angina pectoris 126 (36) 17 (45)
Transient ischemic attack
Previous revascularization
Rutherford classification
None 2 (1)
Mild claudication 38 (11)
Moderate claudication 167 (48)
Severe claudication 141 (41)
Ischemic rest pain 17 (45)
Critical ischemia with
minor ulcer
21 (55)
Critical ischemia major
ulcer
0 (0)
Exercise data at baseline
(mean  SD)*
ABPI at rest 0.62  0.19 0.52  0.25
ABPI after exercise 0.39  0.23 0.38  0.33
Walking distance (meter) 201  93 101  110
ABPI, Ankle brachial pressure index.
*For some patients information on these baseline characteristics was miss-
ing. The percentages (in parenthesis) refer to the number of patients for
whom data was available.the score on dimensions measuring similar constructs suchas physical functioning of the SF-36 and the dimension
activities of the VascuQol.
We also performed a subgroup analysis in patients with
claudication without any comorbid disease, excluding all
patients with diabetes mellitus, cerebrovascular accident,
myocardial infarction, angina pectoris, congestive heart
failure, renal transplant, or severe renal failure needing
dialysis. This left 251 patients for analysis.
RESULTS
At baseline, the VascuQol, SF-36, and EuroQol-5D
were returned by 443 of 450 patients. The questionnaires
of 7 patients were not returned owing to noncompliance
(n  4), comorbidity (n  1), or death (n  2). After 6
months of follow-up, 386 patients returned questionnaires.
No follow-up occurred in 64 patients because of noncom-
pliance (n 35), comorbidity (n 11), or death (n 18).
All returned questionnaires had high completion rates for
the individual dimensions that varied from 98.7% to 99.5%
for EuroQol-5D, 98.7% to 99.7 % for VascuQol, and from
97.5% to 99.5% for SF-36.
Of the 386 patients who had returned their question-
naires after follow-up, 348 patients had intermittent clau-
dication and 38 patients had critical ischemia. Table I
shows the baseline characteristics of these patients. Figure 1
shows the number of patients who returned their question-
naires at follow-up and underwent conservative or interven-
tional treatment. Of the 91 patients who underwent sur-
gery, the time interval between the date of surgery and the
return of their follow-up questionnaire was more than 2
months for 71 patients (78%).
Cross-sectional construct validity. The construct va-
lidity was determined separately for patients with claudica-
tion and critical ischemia. Table II presents the mean values
of all questionnaires after the patients were classified into
two groups based on the respective indicators of disease
severity at baseline. All questionnaires of patients with
claudication and critical ischemia showed higher mean
values of QOL in patients with less severe disease compared
with patients with more severe disease, irrespective of the
indicators of disease severity (Table II). Moreover, all QOL
scores in critical ischemia patients were lower than the
QOL scores in patients with claudication (Table II). These
results indicate that all three questionnaires meet the expec-
tation that more severely diseased patients have lower
scores on QOL.
A comparison of AUCs calculated from total scores of
all three questionnaires resulted in only minor differences
between these AUCs. These differences were not statisti-
cally significant (all P .05) (Table II). Likewise, the ROC
curve in Fig 2 shows no differences between the AUCs after
claudication patients were classified into two groups ac-
cording to the Rutherford classification.
Additional analyses comparing the dimensions activity
(VascuQol) with physical functioning (SF-36) showed mi-
nor differences among the AUCs. However, the AUC for
discriminating between claudication patients with higher
versus lower than median walking distance was significantly
cantly
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(P .002). The subgroup analysis for claudication patients
without any comorbid disease showed similar results.
Longitudinal construct validity. Patients with clau-
Table II. Cross-sectional construct validity
Mean QOL values
Patients with claudication (N 
Walking distance
R
cla
200 m* 200 m* AUC 4†
VascuQol
Activity 3.1 3.9 0.68 3.1
Symptoms 4.4 4.7 0.59 4.3
Pain 3.3 3.7 0.60 3.3
Social 3.8 4.7 0.67 3.8
Emotional 4.0 4.6 0.61 4.0
Total 3.7 4.2 0.65 3.6
SF-36
Physical functioning 33 51 0.76¶ 34
Bodily pain 44 52 0.61 43
Role physical
functioning
27 51 0.66 28
General health 51 57 0.58 53
Total 0.75 0.78 0.68 0.75
EuroQol-5D 0.52 0.63 0.61 0.49
QOL, Quality of life; N, number of patients who returned their questionn
questionnaire; SF-36, Short Form 36 questionnaire; EuroQol-5D, European
*For patients with claudication, the median value (200 m) of walking distan
mild disease (200 m).
†The median value of Rutherford classification: 1-3 represents none-to-mo
‡For patients with critical ischemia the median value of walking distance wa
§For patients with critical ischemia the median value of Rutherford classifica
ie, the group with severe disease) and Rutherford category 5 (patients with
¶AUC for the SF-36 based on score on dimension physical activity is signifi
activity (P  .002).
Fig 2. Receiver operating characteristic (ROC) curve at baseline
for patients with claudication. P 1-2  .6, (P value comparing
AUCs VascuQol with SF-36). P 1-3  .8, (P value comparing
AUCs VascuQol with EuroQol-5D). P 2-3  .8; (P-value com-
paring AUCs SF-36 with EuroQol-5D).dication were separated from critical ischemia patients, andTable III shows the subsequent mean values of change in
QOL for patients with large improvement versus patients
with small or no improvement at 6 months after imaging
workup. All three questionnaires had higher mean values
for change in QOL in patients with larger improvement
compared with patients with small to no improvement.
This trend was observed irrespective of which indicator of
disease severity is considered.
To determine which questionnaire detected the largest
change after follow-up, ROC curves and AUCs were calcu-
lated based on change in the total scores (Table III and Fig
3).AUCs for the VascuQol were higher than the AUCs for
the SF-36, which was significant for discriminating be-
tween claudication patients with more and less thanmedian
change in Rutherford classification (AUCs 0.82 vs 0.67,
P  .001) (Table III). The group of critical ischemia
patients was too small to demonstrate statistical differences.
The AUCs for the VascuQol were also higher than the
AUCs for the EuroQol-5D. Significant differences in
AUCs were found for discriminating between more and
less than median change in the Rutherford classification for
both patients with claudication (0.82 vs 0.68) and patients
with critical ischemia (0.81 vs 0.51) (P .003). This is also
expressed in Fig 3, which shows a higher ROC curve for the
VascuQol compared with ROC curves for the SF-36 and
EuroQol-5D, after classifying claudication patients based
Patients with critical ischemia (N  57)
ford
tion Walking distance
Rutherford
classification
† AUC  30 m‡ 30 m‡ AUC  6§  5§ AUC
0.65 2.3 2.6 0.55 2.5 2.5 0.52
0.57 3.0 3.3 0.55 3.1 3.3 0.51
0.58 2.3 2.1 0.46 2.4 2.0 0.36
0.60 2.7 3.1 0.57 2.9 3.0 0.48
0.59 2.9 3.4 0.59 3.1 3.5 0.56
0.62 2.9 2.9 0.57 2.8 2.8 0.52
0.66 28 31 0.54 27 31 0.56
0.61 29 34 0.61 31 35 0.58
0.60 21 16 0.46 20 17 0.46
0.51 38 38 0.48 38 37 0.46
8 0.64 0.71 0.73 0.57 0.71 0.73 0.59
2 0.63 0.29 0.43 0.62 0.31 0.40 0.57
t baseline; AUC, area under the curve; VascuQol, Vascular Quality of Life
ity of Life 5D questionnaire.
s used as cut-off value to define patients with severe disease ( 200 m) and
claudication, 4 represents severe claudication.
.
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ic rest pain, ie, the group with “mild disease”).
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(VascuQol) were compared with physical functioning (SF-
36), the AUCs for the VascuQol were higher than the
AUCs for the SF-36 (Table III). The AUC for the Vascu-
Table III. Longitudinal construct validity after 6 months
Mean change () in
QOL
Patients with claudication (N 
Walking distance*
R
clas
 7m* 7m* AUC  0
VascuQol
 Activity 0.9 1.4 0.58 0.1
 Symptoms 0.6 1.0 0.59 0.1
 Pain 0.9 1.4 0.58 0.3
 Social 0.6 1.0 0.59 0.0
 Emotional 0.6 1.1 0.60 0.0
 Total 0.8 1.2 0.60 0.1
SF-36
 Physical functioning 11 18 0.57 1 2
 Bodily pain 8 14 0.57 1 1
 Role physical
functioning
13 17 0.55 2 2
 General health 1 0 0.51 3
 Total 0.01 0.02 0.53 0.00
 EuroQol-5D 0.06 0.11 0.55 0.02
QOL, Quality of life; N, number of patients who returned their questionn
Quality of Life questionnaire; SF-36, Short Form 36 questionnaire; EuroQo
*The median value 7 and 3 m of the change in walking distance was used as
large improvement (7 and 3 m) for patients with claudication and critica
improvement seems small, due to the low median values. However, for the
142 m for patients with claudication and critical ischemia, respectively.
†Patient group with an upward shift by one of more (1) clinical categorie
‡Patient group with an upward shift by four of more ( 4) clinical categori
§AUC for the VascuQol based on change in score on dimension activity is
dimension physical activity (P  .05).
¶AUC for the VascuQol based on change in total score is significantly high
#AUC for the VascuQol based on change in total score is significantly high
Fig 3. Receiver operating characteristic (ROC) curve after fol-
low-up for patients with claudication. P 1-2  .001; (P value
comparing AUCs VascuQol with SF-36). P 1-3  .001; (P value
comparing AUCs VascuQol with EuroQol-5D). P 2-3  .7, (P
value comparing AUCs SF-36 with EuroQol-5D).Qol (0.82) for discriminating between claudication pa-tients with more and less than a median change in Ruther-
ford classification was significantly higher than the AUC for
the SF-36 (0.77) (P .002). The subgroup analysis for
claudication patients without any comorbid disease showed
similar results.
DISCUSSION
The present study shows that the generic and the
disease-specific questionnaires performed equally well in
discriminating severe from mild disease at baseline in both
patients with claudication and critical ischemia (Table II).
However, the disease-specific questionnaire VascuQol was
better in discriminating a large versus a small change in
disease severity after follow-up than the generic question-
naires SF-36 and the EuroQol-5D (Table III) for both
patients with claudication and critical ischemia. These re-
sults suggest that the VascuQol is a better questionnaire
than the SF-36 or EuroQol-5D to detect change inQOL in
patients with PAD.
Our findings are consistent with other studies that
showed the disease severity of PAD at baseline and change
in disease severity are reflected by QOL scores as measured
by VascuQol, SF- 36, and EuroQol-5D.4,13,21,22 How-
ever, the unique feature of our study is the statistically
grounded comparison of a disease-specific questionnaire
w-up
) Patients with critical ischemia (N  38)
ford
ion Walking distance*
Rutherford
classification
AUC  3m*  3m* AUC 3 4‡ AUC
0.82
§
0.7 1.6 0.72 0.4 1.4 0.74
0.75 1.4 2.2 0.67 0.8 2.0 0.78
0.80 1.4 2.7 0.76 0.7 2.2 0.83
0.72 0.9 1.3 0.62 0.5 1.5 0.72
0.79 0.4 1.4 0.76 0.2 1.1 0.74
0.82¶# 0.9 1.8 0.76 0.5 1.6 0.81#
0.77 2 11 0.66 4 12 0.68
0.73 18 27 0.52 2 27 0.77
0.63 0 23 0.69 2 18 0.58
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0.67 0.01 0.05 0.60 0.02 0.04 0.63
0.68 0.11 0.37 0.74 0.18 0.21 0.51
fter 6 months follow-up. AUC, area under the curve; VascuQol, Vascular
European Quality of Life 5D questionnaire.
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during follow-up.
A frequently applied method for comparing question-
naires is to calculate correlation coefficients.4,13,21,22 How-
ever, we opted for calculating areas under the ROC curves
because this provides a method to quantify the differences
between the questionnaires with respect to cross-sectional
and longitudinal construct validity and these differences
can easily be tested.
The reason for the overall limited use of disease-specific
questionnaires might be that these questionnaires are rela-
tively new and have undergone a limited validation pro-
cess.12 One recommended disease-specific questionnaire,
the Claudication Scale (CLAU-S), has often been used in
trials that used specific medication, but it measures only
QOL in patients with intermittent claudication.23-25 We
preferred to use the VascuQol, because both patients with
intermittent claudication and patients with critical isch-
aemia were included in our study.
A major problem in comparing the validity of QOL
questionnaires is the lack of a gold standard. The approach
in this study is driven by the assumption that disease sever-
ity is a major determinant of quality of life. However, it
might be argued that “objective” disease severity is not
always directly related to loss of QOL, and other parame-
ters, such as the patients’ expectations of life and comor-
bidity, are also major determinants of QOL. To avoid
confounding by comorbidity, we restricted the study pop-
ulation to patients without severe comorbidity. We think
the assumption is valid that differences in disease severity in
such a population are reflected by differences in QOL.
A limitation of this present study was that not all
dimensions of the SF-36 questionnaire were used. Selec-
tion of dimensions may have induced loss of information
and consequently, a suboptimal calculation of a total score
on the SF-36. Our reason for selecting specific dimensions
was that the length of the SF-36 has been shown to be
unfavorable for full completion of all questions by the
patient.26 In our opinion, full completion of a selected
number of dimensions was more important than poor
completion of all dimensions in the SF-36 questionnaire.
Indeed, the completion rate of the four dimensions of the
SF-36 was substantially higher (range, 98% to 99%) than
reported in previous studies that used all dimensions of the
SF-36 (70% to 91%).26,27 We used the dimensions physical
functioning, role physical functioning, bodily pain, and
general health because these items have proved to be the
most responsive in detecting changes after follow-up in
patients with PAD.8,13,15 The dimensions and items that
were excluded have previously been shown to change little
during follow-up of patients with PAD.8,13,15 Based on the
results of these studies, we assumed that the excluded items
would remain constant in our population and would not
affect the change in the total score of the SF-36.8,13,15
Another limitation of our study was the substantial
proportion of patients with missing data after follow-up
because 64 patients did not return their questionnaire. It is
not to be expected that the missing data influenced theoutcome of the comparison between the questionnaires.
Moreover, for practical reasons, the SF-36 was returned by
mail instead of being administered by a third party; how-
ever, we had high completion rates of the returned ques-
tionnaires, indicating that patients had no difficulties com-
pleting the questionnaires.
Furthermore, it must be noted that the results of this
study pertain only to a subgroup of patients with PAD,
namely, patients who needed imaging work-up to deter-
mine treatment policy. From a clinical viewpoint, the ques-
tion of which type of questionnaire has the best ability to
detect changes in QOL after treatment is most relevant for
this subgroup. The results of this study, however, may not
be generalized to patients with uncomplicated claudication
who do not need an image work-up.
Calculation of the total score of the SF-36 has been
criticized in the literature because it has not been thor-
oughly validated in patients, although some studies showed
that the total score of the SF-36 is a valid measure.28-30 A
comparison of total scores of different questionnaires might
bemore valid to determine which questionnaire is preferred
instead of comparing several not always corresponding
health dimensions. Although our calculation of the total
score of the SF-36 was difficult because not all items were
included in our study, the AUCs based on the total score of
the SF-36 were similar to the AUCs based on the scores in
the four individual dimensions of the SF-36 (Tables II and
III). Furthermore, to verify our results of comparing AUCs
based on total scores of all questionnaires, we compared in
additional analyses the AUCs based on the score of the
most responsive dimension of the SF-36 (physical activity)
with the corresponding dimension of the VascuQol (activ-
ities). These additional analyses showed similar results as
the comparison of AUCs based on total scores (Tables II
and III).
Practical application. The treatment of patients with
PAD is, or should be, predominantly aimed at improving
QOL.7-11 QOL is important to evaluate different treat-
ment strategies and their cost-effectiveness. Therefore, as-
sessment of QOL could be a stronger measure for evaluat-
ing the effects of treatment than the traditional clinical
outcomes such as ABPI. As was demonstrated in other
studies, changes in ABPI correlate poorly with changes in
QOL scores.5,13,15 This finding indicates that a frequently
used “hard” measure of outcome does not always reflect
the patient’s perceived QOL.
Currently, most patients with claudication are treated
conservatively, and only those patients who have severe
symptoms according to the opinion of the surgeon are
considered for interventional treatment. Hicken et al2
showed that surgeons misjudged their patients’ QOL in
everyday clinical practice. Consequently, the surgeons
might assign interventional treatment to the wrong pa-
tients. Standardized assessments of QOL bymeans of ques-
tionnaires can help surgeons decide which patients are
eligible for interventional treatment. Based on the assump-
tion that disease severity is an important determinant of
QOL, the results of our study favor the use of the VascuQol
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the SF-36 and EuroQol-5D for assessing changes in QOL
in patients with PAD.
Conclusion. All three questionnaires VascuQol, SF-
36, and EuroQol-5D performed equally well in assessing
QOL at baseline in patients with PAD. The disease-specific
VascuQol is superior to the generic questionnaires SF–36
and EuroQol-5D with respect to the detection of changes
in QOL after follow-up. The VascuQol is the preferred
questionnaire as outcome measure for QOL in future trials
and clinical follow-up of patients with PAD.
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